Welcome to our dedicated page for United States Antimony SEC filings (Ticker: UAMY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Antimony tonnage tables, reclamation liabilities, fluctuating smelter yields—United States Antimony’s SEC documents can overwhelm even experienced analysts. Whether you are searching for “United States Antimony SEC filings explained simply” or need the latest “United States Antimony insider trading Form 4 transactions”, the raw EDGAR feed alone rarely answers core valuation questions.
Stock Titan solves this problem with an AI layer built for complex resource companies. Our system scans every 10-K, 10-Q, 8-K and proxy in real time, then delivers plain-English summaries alongside the original text. You’ll see environmental footnotes, mine-life assumptions and segment revenue called out automatically. Need to monitor Form 4 activity? We provide “United States Antimony Form 4 insider transactions real-time” alerts so you learn when executives buy or sell before the market digests the move. Looking for production trends? Our dashboards link the “United States Antimony quarterly earnings report 10-Q filing” to historical ore grades and cash-cost metrics.
Here’s what becomes effortless:
- Compare year-over-year mine output using data extracted from the annual report 10-K simplified
- Track executive stock transactions Form 4 against antimony price swings
- Review proxy statement executive compensation details next to production bonuses
- Decode 8-K material events explained—from furnace shutdowns to offtake agreements
With comprehensive coverage and instant AI commentary, Stock Titan turns hundreds of pages into decisive insight. Stop skimming PDFs and start understanding United States Antimony SEC documents with AI in minutes.
United States Antimony Corp (UAMY) director Michael A. McManus Jr. reported selling 50,000 shares of common stock on 10/01/2025 at a reported price of $7.316 per share. After the sale he beneficially owns 531,965 shares. The Form 4 was signed on 10/02/2025 and shows the transaction as a direct disposition by a director.
United States Antimony Corp (UAMY) filed a Form 144 disclosing a proposed sale of 50,000 common shares with an aggregate market value of $350,000. The filing states the shares represent part of the company's outstanding 120,723,320 shares and that the approximate sale date is 10/01/2025 through the NYSE via Merrill Lynch. The shares were acquired on 05/15/2024 as a stock bonus from US Antimony Corp, and no sales by the same person were reported in the past three months. The filer certifies they are unaware of any undisclosed material adverse information about the issuer.
United States Antimony Corp (UAMY) filed a Form 144 reporting a proposed sale of 12,500 common shares through Merrill EDGE (Jacksonville, FL) on the NYSE American with an approximate aggregate market value of $98,375. The shares were acquired on 01/29/2025 as restricted stock vesting from the issuer, totaling 33,333 shares received on that date and paid as compensation. The filer reports 120,723,320 shares outstanding and lists an approximate sale date of 09/24/2025. The filing states there were no securities sold in the past three months by the selling person and includes the standard representation that the seller is not aware of undisclosed material adverse information.
Form 144 filed for United States Antimony Corp (UAMY) reporting a proposed sale of 40,000 common shares with an aggregate market value of $245,000, listed for an approximate sale date of 09/29/2025 on NYSE American through broker Canaccord Genuity.
The filing shows the shares were originally acquired in open-market cash purchases on 08/18/2022 and 08/19/2022 in four lots totaling the 40,000 shares, with payment settled in cash. The issuer has 120,723,320 shares outstanding. The filer reports no sales of these securities in the past three months and includes the standard representation that the seller is not aware of undisclosed material adverse information.
Jeffrey R. Fink, an officer and director of United States Antimony Corp (UAMY), reported the sale of 12,500 shares of the company's common stock on September 24, 2025 at a reported price of $7.87 per share. After the transaction he beneficially owned 66,833 shares. The Form 4 was signed on October 2, 2025. The filing discloses a straightforward open-market disposition by an insider and contains no derivative transactions or additional explanations.
Richard R. Isaak, Senior Vice President and Chief Financial Officer of United States Antimony Corp (UAMY), reported a sale of 50,000 shares of the company's common stock on 10/01/2025 at a price of $7 per share. Following the reported disposition, he beneficially owns 251,744 shares. The Form 4 was signed by Mr. Isaak on 10/01/2025.
Form 144 filing for UNITED STATES ANTIMONY CORP (UAMY) reports a proposed sale of 50,000 common shares through Merrill Lynch in New York with an aggregate market value of $365,791.80 and an approximate sale date of 10/01/2025. The filer reports acquiring 135,000 of the shares on 08/14/2024 in an open market purchase paid in cash. The issuer has 128,727,843 shares outstanding as stated. The notice includes the filer’s representation that they are not aware of any undisclosed material adverse information about the issuer.
Gary C. Evans, Chairman & CEO and a director of United States Antimony Corp (UAMY), reported a purchase of 100,000 shares of the company on 09/26/2025 at a price of $6.132 per share. Following the transaction, Mr. Evans beneficially owns 2,378,818 shares. The Form 4 was filed as a single reporting person filing and bears Mr. Evans' signature dated 09/26/2025.
Gary C. Evans, Chairman & CEO of United States Antimony Corp (UAMY), reported grants on 05/27/2025 consisting of 750,000 restricted stock units (RSUs) and a stock option covering 750,000 shares with an exercise price of $2.57. One-third of the RSU award (250,000 shares) vested on 05/27/2025 and the remaining two tranches vest on 05/27/2026 and 05/27/2027, subject to continued service and shareholder approval of the issuer’s Amended and Restated 2023 Equity Incentive Plan. The option award vests only upon meeting specified performance measures anytime during its 10-year term and is also subject to shareholder approval. The Form 4 was signed by Mr. Evans on 09/16/2025.
FAQ
What is the current stock price of United States Antimony (UAMY)?
What is the market cap of United States Antimony (UAMY)?
